Lipid nanoparticles deliver gene editingthrough liver LDLR; therefore, it is not efficient to use standard lipidnanoparticles as a delivery system in patients with HoFH; nevertheless, Kasiewiczet al. [74] designed a new lipid nanoparticle system includedN-acetylgalactosamine (GalNAc) with the ability to bind to the asialoglycoproteinreceptor (ASGPR) to target ANGPTL3 in nonhuman primates with HoFH. Here, LDLR is linked to homozygous familial hypercholesterolemia.